The physical and digital biobank supports the integration of artificial intelligence in acute care diagnostics development.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

Last week, readers were most interested in a story about concerns about BillionToOne's Unity NIPT due to false negative results.

The company said its preliminary revenues for the fourth quarter were at least $21 million, and its full-year 2025 revenues are expected to grow to $77 million.

The firm said it has appointed Abhishek Jain, a veteran of CareDx and Agilent Technologies, to be its next chief financial officer.

For full-year 2025, MDxHealth's preliminary revenues are $109 million, up 21 percent from 90.0 million in 2024. It billed 49,180 tissue-based units, up from 18 percent year over year, and 71,920 ...

The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

The funding will support final development, clinical validation, regulatory approval, and commercial launch of an ultra-rapid AST platform.

The next phase of funding will allow the team to launch a clinical trial to test a novel way of making early gastric tumors easier to identify during endoscopy procedures.

The STELLAR-316 trial will use Natera's Signatera assay to identify MRD-positive patients for trial enrollment and to monitor therapy response.

Aranscia will provide software solutions to facilitate the delivery of results from InterVenn's flagship glycoproteomic liquid biopsy test.